Moreover, we found that ID1 expression was increased in clinical samples of BMC from patients with CMML at diagnosis harboring both ASXL1 and RUNX1 mutations compared to either ASXL1 or RUNX1 mutations (Fig. 5d). This evidence concerns the gene RUNX1 and chronic myelomonocytic leukemia.